Curis (NASDAQ:CRIS - Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Curis to post earnings of ($1.94) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Curis (NASDAQ:CRIS - Get Free Report) last issued its earnings results on Thursday, February 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.12). Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The firm had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.95 million. During the same period in the previous year, the firm earned ($2.40) earnings per share. On average, analysts expect Curis to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Curis Trading Up 4.2 %
Curis stock traded up $0.64 during midday trading on Wednesday, reaching $15.99. The stock had a trading volume of 10,272 shares, compared to its average volume of 33,881. Curis has a 12 month low of $3.80 and a 12 month high of $19.60. The company has a market capitalization of $94.18 million, a P/E ratio of -1.78 and a beta of 3.72. The company has a fifty day moving average price of $12.42 and a two-hundred day moving average price of $10.64.
Wall Street Analyst Weigh In
Separately, HC Wainwright decreased their target price on Curis from $51.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, February 9th.
Read Our Latest Research Report on Curis
About Curis
(
Get Free Report)
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Featured Stories
Before you consider Curis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curis wasn't on the list.
While Curis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
